journal article·2014-01-08

Assessing the in Vivo Efficacy of Doxorubicin Loaded Hyaluronan Nanoparticles

Mohammad H. El-Dakdouki, Jingguang Xia, David C. Zhu, Herbert Kavunja, Jessica Grieshaber, Sandra O’Reilly, J. Justin McCormick, Xuefei Huang

Publisher page

Abstract

Magnetic nanoparticles are attractive platforms for biomedical applications including diagnosis and treatment of diseases. We have shown previously that hyaluronan-coated superparamagnetic iron oxide nanoparticles (HA-SPIONs) enhanced the efficacy of the conjugated anticancer drug doxorubicin (DOX) in vitro against drug-sensitive and drug-resistant human ovarian cancer cells. In this manuscript, we report our findings on the efficacy of DOX loaded HA-SPIONs in vivo using subcutaneous and intraperitoneal SKOV-3 ovarian tumor models in nude mice. The accumulation of the nanoparticles in subcutaneous tumors following an intravenous nanoparticle administration was confirmed by magnetic resonance imaging, and its distribution in the tumors was evaluated by confocal microscopy and Prussian blue staining. DOX delivered by nanoparticles accumulated at much higher levels and distributed wider in the tumor tissue than intravenously injected free DOX, leading to significant reduction of tumor growth. The IVIS Spectrum for in vivo bioluminescence imaging was used to aid in therapy assessment of the DOX-loaded nanoparticles on intraperitoneal ovarian tumors formed by firefly luciferase expressing human ovarian SKOV-3 cells. DOX-loaded HA-SPIONs significantly reduced tumor growth, delayed tumor development, and extended the survival of mice. Thus, utilizing HA-SPIONs as drug delivery vehicles constitutes a promising approach to tackle CD44 expressing ovarian cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ovarian cancer diagnosis and treatment · Nanoparticle-Based Drug Delivery · Intraperitoneal and Appendiceal Malignancies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Beirut Arab University, P.O. Box 11-5020 Riad El Solh 11072809, Beirut, Lebanon

Department of Chemistry, Michigan State University, Chemistry Building, Room 426, 578 South Shaw Lane, East Lansing, Michigan 48824, United States

Departments of Radiology and Psychology, Michigan State University, East Lansing, Michigan 48824, United States

Carcinogenesis Laboratory, Department of Microbiology & Molecular Genetics, Michigan State University, East Lansing, Michigan 48824, United States

Research Technology and Support Facility, Imaging-IVIS, Biomedical and Physical Sciences Building, Michigan State University, East Lansing, Michigan 48824, United States

Funding

National Cancer Institute

References (52)

Show source-provided references
1. American Cancer Society · 2013
2. Dinh P. · Crit. Rev. Oncol. Hematol. · 2008 · 67 · 10310.1016/j.critrevonc.2008.01.012 ↗
3. Ozols R. F. · J. Clin. Oncol. · 2003 · 21 · 319410.1200/JCO.2003.02.153 ↗
4. Kalachand R. · Drugs · 2011 · 71 · 94710.2165/11591740-000000000-00000 ↗
5. Bast R. C. · Nat. Rev. Cancer · 2009 · 9 · 41510.1038/nrc2644 ↗
6. Goff B. A. · Cancer · 2000 · 89 · 206810.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z ↗
7. Gore M. E. · Gynecol. Oncol. · 1990 · 36 · 20710.1016/0090-8258(90)90174-J ↗
8. Poveda A. · Ann. Oncol. · 2011 · 22 · 3910.1093/annonc/mdq352 ↗
9. de Placido S. · J. Clin. Oncol. · 2004 · 22 · 263510.1200/JCO.2004.09.088 ↗
10. Welch S. A. · Int. J. Gynecol. Cancer · 2010 · 20 · 78710.1111/IGC.0b013e3181e273a8 ↗
11. Wagner U. · Gynecol. Oncol. · 2007 · 105 · 13210.1016/j.ygyno.2006.10.053 ↗
12. Agarwal R. · Nat. Rev. Cancer · 2003 · 3 · 50210.1038/nrc1123 ↗
13. Yap T. A. · Nat. Rev. Cancer · 2009 · 9 · 16710.1038/nrc2583 ↗
14. Banerjee S. · Oncologist · 2009 · 14 · 70610.1634/theoncologist.2009-0013 ↗
15. van der Bilt A. R. M. · Crit. Rev. Oncol. Hematol. · 2012 · 84 · 22410.1016/j.critrevonc.2012.03.006 ↗
16. Markman M. · J. Oncol. · 2010 · 2010 · 17142510.1155/2010/171425 ↗
17. Kanwar J. R. · Nanomedicine · 2012 · 8 · 39910.1016/j.nano.2011.08.006 ↗
18. Moghimi S. M. · Nanomedicine · 2011 · 7 · 51510.1016/j.nano.2011.05.001 ↗
19. Baker M. · Nat. Methods · 2010 · 7 · 95710.1038/nmeth1210-957 ↗
20. Lammers T. · Clin. Cancer Res. · 2012 · 18 · 488910.1158/1078-0432.CCR-12-1414 ↗
21. Huang Y. · Nanoscale · 2012 · 4 · 613510.1039/c2nr31715j ↗
22. Ma P. · Nano Today · 2013 · 8 · 31310.1016/j.nantod.2013.04.006 ↗
23. Ferrari M. · Nat. Rev. Cancer · 2005 · 5 · 16110.1038/nrc1566 ↗
24. Bu H. H. · Sci. China: Chem. · 2010 · 53 · 222610.1007/s11426-010-4142-5 ↗
25. El-Dakdouki M. H. · RSC Adv. · 2011 · 1 · 144910.1039/c1ra00737h ↗
26. El-boubbou K. · J. Am. Chem. Soc. · 2007 · 129 · 1339210.1021/ja076086e ↗
27. El-Dakdouki M. H. · Biomacromolecules · 2012 · 13 · 114410.1021/bm300046h ↗
28. El-boubbou K. · J. Am. Chem. Soc. · 2010 · 132 · 449010.1021/ja100455c ↗
29. 10.1007/s11095-013-1021-810.1007/s11095-013-1021-8 ↗
30. Li H. · Chem. Commun. · 2012 · 48 · 338510.1039/c2cc17852d ↗
31. Kamat M. · Bioconjugate Chem. · 2010 · 21 · 212810.1021/bc100354m ↗
32. Kouyoumdjian H. · ACS Chem. Neurosci. · 2013 · 4 · 57510.1021/cn3002015 ↗
33. Prayer L. · Br. J. Radiol. · 1993 · 66 · 41510.1259/0007-1285-66-785-415 ↗
34. Yigit M. V. · Pharm. Res. · 2012 · 29 · 118010.1007/s11095-012-0679-7 ↗
35. 10.1038/ncomms326610.1038/ncomms3266 ↗
36. Lee N. · Chem. Soc. Rev. · 2012 · 41 · 257510.1039/C1CS15248C ↗
37. Chen B. · Int. J. Nanomed. · 2008 · 3 · 277
38. Li K. · Int. J. Nanomed. · 2013 · 8 · 1867
39. Chen B. · Int. J. Nanomed. · 2009 · 4 · 7310.2147/IJN.S5093 ↗
40. Jiang Z. · Int. J. Nanomed. · 2009 · 4 · 107
41. El-Dakdouki M. H. · Nanoscale · 2013 · 5 · 389510.1039/c3nr33777d ↗
42. El-Dakdouki M. H. · Nanoscale · 2013 · 5 · 390410.1039/c3nr90022c ↗
43. Na H. B. · Adv. Mater. · 2009 · 21 · 213310.1002/adma.200802366 ↗
44. Seymour L. W. · Biochem. Pharmacol. · 1990 · 39 · 112510.1016/0006-2952(90)90293-T ↗
45. Lee C. C. · Proc. Natl. Acad. Sci. U.S.A. · 2006 · 103 · 1664910.1073/pnas.0607705103 ↗
46. Minchinton A. I. · Nat. Rev. Cancer · 2006 · 6 · 58310.1038/nrc1893 ↗
47. Primeau A. J. · Clin. Cancer Res. · 2005 · 11 · 878210.1158/1078-0432.CCR-05-1664 ↗
48. Ceelen W. P. · Nat. Rev. Clin. Oncol. · 2010 · 7 · 10810.1038/nrclinonc.2009.217 ↗
49. Markman M. · Int. J. Gynecol. Cancer · 2008 · 18 · 3310.1111/j.1525-1438.2007.01102.x ↗
50. Boven E. · Eur. J. Cancer · 1990 · 26 · 98310.1016/0277-5379(90)90626-5 ↗
51. Gore M. · J. Clin. Oncol. · 2006 · 24 · 452810.1200/JCO.2006.06.0376 ↗
52. Vergote I. · Oncologist · 2008 · 13 · 41010.1634/theoncologist.2007-0224 ↗